SCIENTIFIC SECRETARY. - Richard Baird, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
|
|
|
- Tyrone McGee
- 8 years ago
- Views:
Transcription
1 PROGRAM
2 CHAIRMEN - Bruce A. Chabner, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA - Hernán Cortés-Funes, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain SCIENTIFIC ADVISORY BOARD - Carlos Arteaga, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tenessee, USA - José Baselga, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA - Hilary Calvert, University of Newcastle, Newcastle, UK - Hernán Cortés-Funes, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain - Johann de Bono, The Royal Marsden, The Institute of Cancer Research, London, UK - José Antonio López Martín, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain - Eric Raymond, AP-HP Hôpital Beaujon, Clichy, France - Josep Tabernero, Hospital General Universitario Vall d'hebron, Barcelona, Spain - Anthony Tolcher, South Texas Accelerated Research Therapeutics, LLC-START, San Antonio, Texas,USA SCIENTIFIC SECRETARY - José Antonio López Martín, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain FACULTY - Álex Adjei, Roswell Park Cancer Institute, Buffalo, New York, USA - Joan Albanell, Hospital Clínic i Provincial Adjunto, Barcelona, Spain - Luis Álvarez Vallina, Hospital Universitario Puerta de Hierro, Madrid, Spain - Jean Pierre Armand, Oncopole, Institut Universitaire du Cancer, Toulouse, France - Carlos Arteaga, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tenessee, USA - Richard Baird, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK - Hilary Calvert, University of Newcastle, Newcastle, UK - Peter Campbell, Wellcome Trust Sanger Institute, Hinxton, UK* - Alfredo Carrato, Hospital Universitario Ramón y Cajal, Madrid, Spain - Andrés Cervantes, Universidad de Valencia, Instituto de Investigación Sanitaria-INCLIVA, Valencia, Spain - Eva Ciruelos, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain - Ramón Colomer, ICO Barcelona, Barcelona, Spain - Hernán Cortés-Funes, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain - Johann de Bono, The Royal Marsden, The Institute of Cancer Research, London, UK - George Demetri, Dana-Farber Cancer Institute, Boston, Massachusetts, USA - Neil Desai, Celgene, Los Angeles, California, USA - Iris Faull, Palex Medical, Sant Cugat del Vallés, Barcelona, Spain - Juan Carlos Lacal, Instituto de Investigaciones Biomédicas, CSIC, Madrid, Spain - Michael Lahn, Eli Lilly and Company, Indianapolis, Indiana, USA - Christophe Le Tourneau, Institut Curie, Paris, France - José Antonio López Martín, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain - Heiko Maacke, Merck Serono, Darmstadt, Germany - Franco Muggia, New York Kaplan Cancer NYU Medical Center, New York, New York, USA - María Fe Paz, Labceutics, Madrid, Spain - Luis Paz-Ares, Hospital Universitario Virgen del Rocío, Sevilla, Spain - Mariano Provencio, Hospital Universitario Puerta de Hierro, Madrid, Spain - Eric Raymond, AP-HP Hôpital Beaujon, Clichy, France - Antoni Ribas, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, California,USA - Jordi Rodón, Hospital General Universitario Vall d'hebron, Barcelona, Spain - Rafael Rosell, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain - Ramón Salazar, Institut Català d Oncologia-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain - Jan Schellens, Nederlands Kanker Instituut, Amsterdam, The Netherlands - Jonathan D. Schwartz, ImClone Systems, Bridgewater, New Jersey, USA - Juan Sepúlveda, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain - Lilian Siu, The Princess Margaret Hospital, Wharton Head and Neck Centre, Toronto, Canada - Marisol Soengas, Centro Nacional de Investigaciones Oncológicas, CNIO, Madrid, Spain - Arturo Soto, PharmaMar SAU, Colmenar Viejo, Madrid, Spain - Josep Tabernero, Hospital General Universitario Vall d'hebron, Barcelona, Spain - Anthony Tolcher, South Texas Accelerated Research Therapeutics, LLC-START, San Antonio, Texas,USA - Giampaolo Tortora, Universitá di Verona, Verona, Italy - Guillermo Velasco, Universidad Complutense de Madrid, Madrid, Spain - Laura Vidal, Hospital Clínic, Barcelona, Spain - Andreas Voss, Caris Life Sciences, Basel, Switzerland - Andrea Wagner, Bayer Pharma Aktiengesellschaft, Berlin, Germany - Timothy Yap, The Royal Marsden, The Institute of Cancer Research, London, UK - Alejandro Yovine, Novartis Oncology, Basel, Switzerland TBC*
3 Wednesday, October am Introduction Hernán Cortés-Funes (Madrid) am Educational Lectures: Personalizing Phase I Clinical Trials Chairman: Hernán Cortés-Funes (Madrid) 9.15 am A Review of Available Methods for Cancer Molecular Profiling Peter Campbell (Hinxton)* 9.35 am The Experience of the Hospital General Universitario Vall d Hebron Jordi Rodón (Barcelona) 9.55 am Should We Personalize Phase I Trials? Johann de Bono (London) am Discussion am Coffee-break pm SYMPOSIUM I: New Achievements Targeting Classic Tumor-Cell Receptors Carlos L. Arteaga (Nashville), Juan Carlos Lacal (Madrid) am Blocking Multiple Human Epidermal Growth Factor Receptors in Solid Tumours Richard Baird (Cambridge) am Clinical Development of TDM-1 Carlos L. Arteaga (Nashville) am Clinical Development of Pertuzumab Eva Ciruelos (Madrid) pm Success and Pitfalls of Anti IGF-1R Inhibition Anthony Tolcher (San Antonio) pm New Achievements in GIST George Demetri (Massachusetts) pm Concomitant EML4-ALK Fusion Gene and Other Molecular Alterations in EGFR-mutant Non-small-cell Lung Cancer Patients Treated with Erlotinib Rafael Rosell (Barcelona) 1.15 pm Discussion 1.45 pm Lunch pm Educational Lecture Jordi Rodón (Barcelona), Juan Sepúlveda (Madrid) The Phase 0 Clinical Trial: Is It Useful in Clinical Development? Hilary Calvert (Newcastle)
4 pm SYMPOSIUM II: Development of Therapies Against Recently Incorporated Receptors Jordi Rodón (Barcelona), Juan Sepúlveda (Madrid) 3.30 pm TGF-β Inhibitors in Clinical Development Michael Lahn (Indianapolis) 3.50 pm Targeting Notch Receptor Pathway in Cancer Giampaolo Tortora (Verona) 4.10 pm The Present and Future Development of Hedgehog Inhibitors in Cancer Anthony Tolcher (San Antonio) 4.30 pm New Antibodies Targeting HER3 Andrés Cervantes (Valencia) 4.50 pm Progress in Immune Checkpoint Blockade: Anti PD-1 Antoni Ribas (Los Angeles) 5.10 pm Understanding and Managing Resistance to BRAF Inhibition Antoni Ribas (Los Angeles) 5.30 pm Discussion 6.00 pm Educational Lecture Jordi Rodón (Barcelona), Juan Sepúlveda (Madrid) 6.30 pm Adjourn Dose Escalation Methods in Clinical Trials Christophe Le Tourneau (Paris) Thursday, October am Educational Lecture Timothy Yap (London), Luis Paz-Ares (Sevilla) Choice of Endpoints and the Use of Biomarkers in Early Phase Clinical Trials Alex Adjei (New York) am SYMPOSIUM III: Targeting Signal Transduction Pathways Timothy Yap (London), Luis Paz-Ares (Sevilla) 9.30 am Developmental Status of wnt Pathway Inhibitors in Cancer Josep Tabernero (Barcelona) 9.50 am Clinical Development of MEK Inhibitors Alex Adjei (New York) am Novel Agents Targeting PI3K Pathway Lilian Siu (Toronto)
5 10.30 am AKT Inhibitors in Clinical Development Timothy Yap (London) am Progress in mtorc Inhibition Josep Tabernero (Barcelona) am Discussion pm Coffee-break pm Educational Lectures Alex Adjei (New York), Alfredo Carrato (Madrid) pm Designing Clinical Trials in the Era of Cancer Genomics Lilian Siu (Toronto) pm The Theory and Practice of Combining Targeted Agents in Early Clinical Trials Johann de Bono (London) 1.10 pm Lunch pm SYMPOSIUM IV: DNA, Cell Cycle and Apoptosis Franco Muggia (New York), Ramón Salazar (Barcelona) 2.30 pm Wee1: a Novel Pathway in p53 Pathway Impairment Jan Schellens (Amsterdam) 2.50 pm Clinical Development of SMAC Mimetics Alex Adjei (New York) 3.10 pm Synthetic dsrna-based Nanocomplexes to Promote Autophagia and Cell Death in Aggressive Melanomas Marisol Soengas (Madrid) 3.30 pm Clinical Development of Checkpoint-1 Inhibitors in Cancer Therapy Michael Lahn (Indianapolis) 3.50 pm Ovarian Cancer: How to Integrate the PARP Inhibitor? Franco Muggia (New York) 4.10 pm Discussion 4.40 pm-5.10 pm Poster Session Chairman: Ramón Colomer (Barcelona)
6 5.10 pm 7.20 pm SATELLITE SYMPOSIUM: PLATFORMS FOR PERSONALISED CANCER THERAPY Chairman: Hernán Cortés-Funes (Madrid) 5.10 pm Bringing Molecular Profiling to Cancer Care and Cancer Research Lilian Siu (Toronto) 5.30 pm Prognostic and Predictive Value of the Oncotype DX Breast Cancer Assay Iris Faull (Barcelona) 5.50 pm Evidence Based Personalized Medicine. A Call for Timely Implementation Andreas Voss (Basel) 6.10 pm Integrated Laboratory Networks: the Forgotten Arm in Personalized Medicine María Fe Paz (Madrid) 6.30 pm Discussion 7.00 pm Adjourn Friday, October am SYMPOSIUM V: Targeting Stroma-Tumor Interactions (I) Eric Raymond (Clichy), Joan Albanell (Barcelona) 9.00 am What Have We Learned After a Decade of Research and Clinical Use of Antiangiogenics? Eric Raymond (Clichy) 9.20 am Development of Dovitinib (TKI258), a FGFR and VEGFR Inhibitor, in Solid Tumors Alejandro Yovine (Basel) 9.40 am Clinical Development of Regorafenib, an Oral Multikinase Inhibitor, in Colorectal Carcinoma Andrea Wagner (Berlin) am Ramucirumab: a Monoclonal Antibody Against VEGFR2 in Clinical Development Jonathan D. Schwartz (Bridgewater) am Discussion am Coffee Break
7 pm SYMPOSIUM VI: Targeting Stroma-Tumor Interactions (II) Jean Pierre Armand (Toulouse), Laura Vidal (Barcelona) am Inhibition of αv Integrins in Cancer Therapy Heiko Maacke (Darmstadt) am New Generation of Antibody-based Reagents for Cancer Therapy Luis Álvarez Vallina (Madrid) pm Targeting the HGF/c-Met Signaling Pathway in Cancer Therapy Luis Paz-Ares (Sevilla) pm Nab-Paclitaxel: More than a Particle-Bound Cytotoxic Agent? Neil Desai (Los Angeles) pm Optimizing the Use of Antiangiogenics with Contrast-enhanced Ultrasonography Jean Pierre Armand (Toulouse) 1.00 pm Discussion pm SYMPOSIUM VII: Miscelanea Mariano Provencio (Madrid), Marisol Soengas (Madrid) 1.30 pm Oncolytic Viruses in Anticancer Research José Antonio López Martín (Madrid) 1.50 pm New Clinical Achievements from a Marine Drug Discovery Process Arturo Soto (Madrid) 2.10 pm New Anticancer Compounds from Terrestrial Surface Sources: the Cannabinoids Guillermo Velasco (Madrid) 2.30 pm Discussion 3.00 pm Closing Remarks José Antonio López Martín (Madrid)
8 Venue Barcelo Marbella C.Granadillas, Urb Guadalmina Alta Marbella Conference Secretariat BN&Co. Congress and Event Management Paseo de la Castellana 179. Entreplanta Madrid - Spain Tel: Fax: m.e.fernandez@bnyco.com Website :
9 ACKNOWLEDGEMENTS: LEADING SPONSOR MAJOR SPONSOR SPONSORS
CNIO Frontiers Meetings Molecular Cancer Therapeutics Madrid, March 8 10, 2010
CNIO Frontiers Meetings Molecular Cancer Therapeutics Madrid, March 8 10, 2010 Organisers S. Gail Eckhardt, University of Colorado Denver, Aurora, USA Roy S. Herbst, The University of Texas MD Anderson
Scientific Committee Hilary Calvert UCL Cancer Institute, London, United Kingdom
Scientific Committee Hilary Calvert UCL Cancer Institute, London, United Kingdom Luca Gianni Fondazione Centro San Raffaele del Monte Tabor, Milan, Italy Ana Maria Gonzalez-Angulo M.D. Anderson Cancer
Scientific Program Call for Abstracts Registration Accommodation
SECOND ANNOUNCEMENT Scientific Program Call for Abstracts Registration Accommodation Deadline for abstract submission: September 20 th, 2011 www.madridbreastcancer2011.com Madrid, November 16-17, 2011
Scientific Programme
Scientific Programme Scientific Committee Hilary Calvert UCL Cancer Institute, London, UK Luca Gianni Ospedale San Raffaele IRCCS, Milan, Italy Ana Maria Gonzalez-Angulo Cristiana Sessa Istituto Oncologico
Scientific Committee. Andrés Cervantes (ESMO, GEICO) Antonio González (ESMO, GEICO) Andrés Poveda (ESMO, GEICO) Jan B. Vermorken (ESMO, GEICO)
Under the Auspices of Organized by 10th International Symposium Advanced Ovarian Cancer: Optimal Therapy. Update Valencia, Spain, 6th March 2015 Directors Andrés Poveda Fundación Instituto Valenciano de
Promises and challenges of developing new drugs in oncology
3 rd International Michelangelo Conference Promises and challenges of developing new drugs in oncology Chairman: Luca Gianni, Milan I July 2-3, 2015 Venue: Museo della Scienza e della Tecnologia Via San
Promises and challenges of developing new drugs in oncology
3 rd International Michelangelo Conference Promises and challenges of developing new drugs in oncology Chairman: Luca Gianni, Milan I July 2-3, 2015 Venue: Museo della Scienza e della Tecnologia Via San
ORGANIZERS Fundación para la Investigación Médica Aplicada FIMA Clínica Universidad de Navarra CUN
D International Symposium: Immunostimulatory monoclonal antibodies and immunomodulation: harvesting the crop Fundación Ramón Areces GENERAL INFORMATION DATES OCTOBER 18th 20th VENUE University of Navarra.
15 th ASEICA INTERNATIONAL CONGRESS
Sevilla 21-23 october 2015 15 th ASEICA Spanish Society for Cancer Research Hotel NH Collection Sevilla. Avda Diego Martinez Barrio, 8, 41013 Sevilla Organizing Committee President Dr. Pedro Lazo-Zbikowski
ESO INSIDE TRACK CONFERENCE. 3 rd FAMILIAL CANCER CONFERENCE. 5-6 June 2008 Madrid, Spain MADRID. Chair: J.Benitez, ES - R. Eeles, UK - H.
ESO INSIDE TRACK CONFERENCE MADRID 3 rd FAMILIAL CANCER CONFERENCE 5-6 June 2008 Madrid, Spain Chair: J.Benitez, ES - R. Eeles, UK - H.Vasen, NL ABSTRACT SUBMISSION Poster abstract deadline 1 APRIL 2008.
Data from an interim analysis from the pivotal Phase 3 trial of YONDELIS in soft tissue sarcoma, SAR-3007, will be presented in an oral presentation
PharmaMar announces new advances in oncology at ASCO 2015 for its compounds YONDELIS and PM1183 in small cell lung cancer, soft tissue sarcoma, and mesothelioma Compelling clinical activity of PM1183 in
Scientific Programme
Scientific Programme Scientific Committee Hilary Calvert UCL Cancer Institute, London, UK Luca Gianni Ospedale San Raffaele IRCCS, Milan, Italy Ana Maria Gonzalez-Angulo The University of Texas, MD Anderson
Scientific Program. Advances in the Treatment of Digestive Tumours. Symposium. International. Under the auspices of: Accredited by:
Advances in the Treatment of Digestive Tumours Scientific Program 22 International Symposium Barcelona (Spain) 11th and 12th December 2014 HOTEL BARCELÓ SANTS Under the auspices of: FEDERATION OF SPANISH
30-31. Advancesincancer immunologyand immunotherapy. announcement. October2015. Royal Olympic Hotel Athens
Advancesincancer immunologyand immunotherapy 30-31 October2015 Royal Olympic Hotel Athens announcement Organizer Hellenic Oncology Research Group (HORG) Symposium chairs N. Kentepozidis, A. Kotsakis, M.
Resolving Cancer Heterogeneity:
INTERNATIONAL SYMPOSIUM ON: Resolving Cancer Heterogeneity: The way to personalised medicine Palazzo della Gran Guardia Verona (Italy), June 30 th July 2 nd, 2016 PROGRAM Organized by: ARC-Net Centre for
Interna'onal congress on Cancer cell death and resistance
! Interna'onal congress on Cancer cell death and resistance May 6 and 7, 2013 h"p://kcelldeath.sciencesconf.org Golf of Seilh Near to Toulouse (Midi-Pyrénées, 31, France) Introduction Content : ² Introduction
1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1
1 page Overview 21 Oct Tuesday 1500 on REGISTRATION 1800 Welcome Reception & Cocktails at the Cape Town International Conference Centre (CTICC) 22 Oct Wednesday 0730 REGISTRATION 0830 OPENING 0900 PLENARY
ESO INSIDE TRACK CONFERENCE. 4 th FAMILIAL CANCER CONFERENCE. 7-8 June 2010 Madrid, Spain. Chair: J. Benítez, ES - H. Vasen, NL MADRID 07/06/10
ESO INSIDE TRACK CONFERENCE MADRID 07/06/10 4 th FAMILIAL CANCER CONFERENCE 7-8 June 2010 Madrid, Spain Chair: J. Benítez, ES - H. Vasen, NL APPLICATION AND ABSTRACT SUBMISSION Poster abstract deadline
13 May 14 May. SESSION 2.- Advances in hearing loss research II Chair: Andrew Forge
13 May 14 May 15:00-17:00 Registration 15:45-16:00 Welcome on behalf of the organizers José María Millán. Unit of Genetics La Fé Hospital. CIBERER. Valencia. Spain. 16:00-16:30 Francesc Palau. CIBERER
PERSONALIZED CANCER TREATMENT A multidisciplinary event
PERSONALIZED CANCER TREATMENT A multidisciplinary event Free Access to the Scientific Sessions March 20 th - 21 st 2015 La Vague de Saint-Paul Saint-Paul de Vence, France Crédit photo Office de Tourisme
FAMILIAL CANCER ESO, CNIO AND NRCO CONFERENCE ON. 19-20 May 2016 Madrid, Spain. Chairs: R. Eeles, UK W.D. Foulkes, CA M. Robledo, ES H.
INSIDE TRACK CONFERENCE ESO, CNIO AND NRCO CONFERENCE ON FAMILIAL CANCER 19-20 May 2016 Madrid, Spain Chairs: R. Eeles, UK W.D. Foulkes, CA M. Robledo, ES H. Vasen, NL FOREWORD The ESO, CNIO and NRCO Conference
Nuevas tecnologías basadas en biomarcadores para oncología
Nuevas tecnologías basadas en biomarcadores para oncología Simposio ASEBIO 14 de marzo 2013, PCB Jose Jimeno, MD, PhD Co-Founder / Vice Chairman Pangaea Biotech SL Barcelona, Spain PANGAEA BIOTECH BUSINESS
Understanding the Molecular and Cellular Biology of Endocrine-Related Cancers. Mont Ste. Odile, Alsace, France 11-14 September 2008
33 rd European Symposium on Hormones and Cell Regulation Understanding the Molecular and Cellular Biology of Endocrine-Related Cancers Mont Ste. Odile, Alsace, France 11-14 September 2008 Invited Speakers:
Programme. Michele Grieco Dipartimento di Scienze Ambientali Seconda Università degli Studi di Napoli Naples, Italy
Programme Invited Speakers: Reuven Agami (The Netherlands), Manuela Baccarini (Austria), Allan Balmain (USA), Daniel Birnbaum (France), Anne-Lise Børresen-Dale (Norway), Carlos Caldas (UK), Silvana Canevari
MADRID 11/06/09 EPIGENETICS AND NEW THERAPIES IN CANCER. 11-12 June 2009 Madrid, Spain ESO INSIDE TRACK CONFERENCE
ESO INSIDE TRACK CONFERENCE MADRID 11/06/09 EPIGENETICS AND NEW THERAPIES IN CANCER 11-12 June 2009 Madrid, Spain Chair: M. Esteller, ES Coordinators: S. Marsoni, IT - M.A. Piris, ES APPLICATION AND ABSTRACT
ESO INSIDE TRACK CONFERENCE. 4 th FAMILIAL CANCER CONFERENCE. 7-8 June 2010 Madrid, Spain. Chair: J. Benítez, ES - H. Vasen, NL MADRID 07/06/10
ESO INSIDE TRACK CONFERENCE MADRID 07/06/10 4 th FAMILIAL CANCER CONFERENCE 7-8 June 2010 Madrid, Spain Chair: J. Benítez, ES - H. Vasen, NL APPLICATION AND ABSTRACT SUBMISSION Poster abstract deadline
WORKSHOPS CURRE T TRE DS I BIOMEDICI E
WORKSHOPS CURRE T TRE DS I BIOMEDICI E 2013 SEDE A TO IO MACHADO BAEZA, SPAI MEMBRA E TRAFFIC AT THE SY APSE. THE CELL BIOLOGY OF SY APTIC PLASTICITY Baeza, Spain 7 th -9 th October 2013 Organized by:
Speakers * * ** * * * * * * * * * * * * * * * * ** * * * * * * * ** * * * * ** * * * * * * ** * * * * * * * *
Quasispecies: past, present and future 30 th anniversary VIII Jornada de Virologia SCB November 17-18, 2008 Institut d Estudis Catalans, Barcelona, Spain Speakers Christof Biebricher Albert Bosch Carlos
eso InSIDe TrACK COnferenCe CAnCer COnferenCe 5-6 June 2014 Madrid, Spain Chairs: j. Benítez, es R. eeles, uk H. Vasen, nl
eso InSIDe TrACK COnferenCe 6 TH familial CAnCer COnferenCe 5-6 June 2014 Madrid, Spain Chairs: j. Benítez, es R. eeles, uk H. Vasen, nl Dear Colleagues, The 6th Familial Cancer Conference hosted once
ELCC 2015 Industry Satellite Symposium The Treatment Roadmap for Squamous NSCLC. Thursday 16th April 2015 13:10 14:20 Room C
ELCC 2015 Industry Satellite Symposium The Treatment Roadmap for Squamous NSCLC Thursday 16th April 2015 13:10 14:20 Room C 1 Contents Programme.... 2 Welcome message.... 3 Faculty biographies.... 4 Symposium
Registrations: www.doctaforum.com/gecp
Organized by Registrations: www.doctaforum.com/gecp CHAIR Rafael Rosell, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona) Under the Auspicies of: Thursday, 17 th November 2011 SESSION 1:
WORKSHOP ON THE CONSERVATION OF THE SUBTERRANEAN CULTURAL HERITAGE. Seville, Spain. 25-27 March 2014
WORKSHOP ON THE CONSERVATION OF THE SUBTERRANEAN CULTURAL HERITAGE Seville, Spain 25-27 March 2014 ORGANIZED BY TECHNOHERITAGE SPANISH NETWORK OF SCIENCE AND TECHNOLOGY FOR THE CONSERVATION OF CULTURAL
GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE
GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE Branko Zakotnik MD, PhD Department of Medical Oncology Institute of Oncology Ljubljana 1 I have no conflict of interest to declare
Dialnet. Author Identification. Eduardo Bergasa eduardo.bergasa@unirioja.es
Dialnet Author Identification Eduardo Bergasa eduardo.bergasa@unirioja.es Fundación Dialnet! Public non-profit foundation! Spin-off of University of La Rioja! Constitution: 2009! In charge of Dialnet portal
Targeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
Regional Young Investigator SIC meeting. 5-6 March 2015
Regional Young Investigator SIC meeting 5-6 March 2015 Aula Magna A - Università Magna Graecia di Catanzaro - Campus Universitario S. Venuta Viale Europa, loc. Germaneto - Catanzaro Invited speakers: Rita
Preliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors
Preliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors John Goldberg 1 *, George Demetri 2, Edwin Choy 3, Lee Rosen 4, Alberto
News Release. Merck KGaA, Darmstadt, Germany, and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma
Your Contacts News Release Merck KGaA, Darmstadt, Germany Media: Markus Talanow +49 6151 72 7144 Investor Relations +49 6151 72 3321 Pfizer Inc., New York, USA Media: Sally Beatty +1 212 733 6566 Investor
WORKSHOP IN LUNG CANCER CLINICAL RESEARCH Improving opportunities in the LATAM region
WORKSHOP IN LUNG CANCER CLINICAL RESEARCH Improving opportunities in the LATAM region April 2016 27-30 Santiago - Chile Hotel Diego de Almagro San Pío X 2530, Providencia, Santiago. INFORMATION www.lungcancerworkshop.cl
INDUSTRY-ACADEMIC-CLINICAL FORUM
INDUSTRY-ACADEMIC-CLINICAL FORUM FUTURE TRENDS IN NANOMEDICINE FOR DIAGNOSTICS AND THERAPY IN ONCOLOGY Parc Científic de Barcelona / Barcelona Science Park 25 th of October of 2012 TABLE OF CONTENTS Agenda
Groundbreaking Collaborative Clinical Trial Launched
Groundbreaking Collaborative Clinical Trial Launched For immediate release Media Contacts: June 16, 2014 Richard Folkers Alison Hendrie 9:00 a.m., EDT Foundation for the NIH Rubenstein Communications (301)
CANCER SUMMER SCHOOL 2014 PROGRAM
CANCER SUMMER SCHOOL 2014 PROGRAM Monday 30 th June 0 Participant Arrival & Coffee Break ED 3 room Presentation of the program Presentation of the participants and of their research interests/experiences
International Symposium on Malignant Pleural Mesothelioma
International Symposium on Malignant Pleural Mesothelioma LONDON 2015 Friday 6th & Saturday 7th November 2015 Jumeirah Carlton Tower Hotel Cadogan Place Knightsbridge London SW1X 9PY United Kingdom Dear
MS: from disease management to patient management
2012 CME Annual meeting in multiple sclerosis MS: from disease management to patient management Valencia, Spain 18-19 May 2012 Dear Colleague On behalf of the Serono Symposia International Foundation we
Comercialización: Transferencia de Conocimiento. María S. Soengas (msoengas@cnio.es) (Spin Off)
Comercialización: Transferencia de Conocimiento María S. Soengas (msoengas@cnio.es) (Spin Off) Comercialización: Transferencia de Conocimiento (Spin Off) 1 2 3 4 The Starting Point: Malignant Melanoma
Future Oncology: Technology, Products, Market and Service Opportunities
Brochure More information from http://www.researchandmarkets.com/reports/296370/ Future Oncology: Technology, Products, Market and Service Opportunities Description: Future Oncology is an analytical newsletter
PROGRAM. Afternoon 14:00-16:00 Works in groups (Tutors from each country). 16:15-17:00 Neuropathology. Danielle Seilhan
First Ramon y Cajal French-Spanish Summer Course on Neurodegenerative Diseases. Topic: Basal Ganglia and Parkinson s disease Collège d Espagne (Cité Internationale Universitaire de Paris) Paris, July 23-27th,
Curriculum Vitae of Luca Gianni
Education: 1976: State University of Milan, Milan, Italy: Medical Doctor with honors 1981: State University of Milan, Milan, Italy: Board- Certified in Internal Medicine Brief Chronology of Activities
POST-CONGRESS SATELLITE MEETINGS May 24 th, 2013. Cancer biomarkers 2013
20 th IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine 45 th Congress of the Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SIBioC) POST-CONGRESS SATELLITE
Liver. Meeting. International. on living donor. transplantation. After Fifteen Years (2000-2015)
Preliminary Program International Meeting ORGANIZED BY Hospital Clínic Hospital Universitari Vall d Hebron Liver Transplantation Units faculty Scientific committee Juan Carlos García-Valdecasas Ramón Charco
Understanding series. new. directions. 1-800-298-2436 LungCancerAlliance.org. A guide for the patient
Understanding series LUNG CANCER: new treatment directions 1-800-298-2436 LungCancerAlliance.org A guide for the patient TABLE OF CONTENTS What s New in lung cancer? Advancements...4 Changes in genes that
International Symposium on Stem Cell Research November 12 to 14, 2009 Buenos Aires, Argentina
International Symposium on Stem Cell Research November 12 to 14, 2009 Buenos Aires, Argentina Organizer: Ministry of Science, Technology and Productive Innovation of Argentina Sponsor: International Society
European Course Minimally Invasive Spinal Surgery Hands-on Course EUCMISS MADRID 2013 Madrid, 14-15 June, 2013
VENUE Anatomy Laboratory Universidad San Pablo CEU Campus Montepríncipe Madrid European Course Minimally Invasive Spinal Surgery ENDOSCOPIC DISCECTOMY XLIF TLIF TUBULAR APPROACHES PERCUT. PEDICULAR SCREWS
ACCORD PROJECT FINAL RESULTS OF THE. 2 nd June, 2015. Rafael Matesanz, on behalf of the ACCORD consortium. Director
FINAL RESULTS OF THE ACCORD PROJECT 2 nd June, 2015 Auditorium MUTUA MADRILEÑA Foundation, MADRID Director Rafael Matesanz, on behalf of the ACCORD consortium Achieving Comprehensive Coordination in Organ
Wednesday, February 24 th, 2016
List of Faculty: Nadeem R. Abu-Rustum, Memorial Sloan Kettering Cancer Center. New York, USA Giovanni Aletti, Istituto Europeo di Oncologia. Milan, Italy Natalia Carballo, David Cibula, General University
Wednesday, February 24 th, 2016
List of Faculty: Nadeem R. Abu-Rustum, Memorial Sloan Kettering Cancer Center. New York, USA Giovanni Aletti, Istituto Europeo di Oncologia. Milan, Italy Natalia Carballo, David Cibula, General University
Successes and Limitations of Targeted Cancer Therapy in Lung Cancer
Successes and Limitations of Targeted Cancer Therapy in Lung Cancer Kenichi Suda a, b Tetsuya Mitsudomi a a Division of Thoracic Surgery, Department of Surgery, Kinki University Faculty of Medicine, Osaka-Sayama,
Resumen Curricular de los Profesores. Jesse Boehm
Resumen Curricular de los Profesores Jesse Boehm Jesse Boehm is the assistant director of the Cancer Program at the Broad Institute. In this role, he works closely with Cancer Program director Todd Golub
Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics
EPAAC WP8 Research Forum - 2 July, Sofitel Hotel Europe, Brussels Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics JY Blay, Past President EORTC
Stem cells: the diverging goals of regenerative medicine and oncology ROME JULY 1-2, 2010 CALL FOR ABSTRACTS
Preliminary Programme INTERNATIONAL CONFERENCE Promoted by: Consiglio Nazionale delle Ricerche In collaboration with Stem cells: the diverging goals of regenerative medicine and oncology CHAIRMEN: KENNETH
15 th ASEICA INTERNATIONAL CONGRESS
Sevilla 21-23 october 2015 15 th ASEICA Spanish Society for Cancer Research Hotel NH Collection Sevilla. Avda Diego Martinez Barrio, 8, 41013 Sevilla Organizing Committee President Dr. Pedro Lazo-Zbikowski
Towards the utilization of cannabinoids as anti-cancer
Towards the utilization of cannabinoids as anti-cancer agents Guillermo Velasco Sestri Levante September 2015 Anti-cancer activity of cannabinoids Munson et al. (1975) Antineoplastic activity of cannabinoids
October 22, 2014. October 23, 2014
Organizers Mercedes Robledo; José María de Campos; James Gnarra; Eric Jonasch Mª Elena Kusak; Susi Martinez; Ilene Sussman; Karina Villar Scientific Committee José María de Campos; Carlos Cenjor; Graeme
Retrieval Centres for HPC-M and HPC-A
A Coruña - (Cod: ES0061) COMPLEXO HOSPITALARIO UNIVERSITARIO JUAN CANALEJO Estrada das Xubias, s/n - 15006 Alcalá de Henares MADRID - (Cod: ES0208) HOSPITAL UNIV. PRINCIPE ASTURIAS Carretera Alcalá-Meco,
Program Co-Chairmen: Dr. John Wagner, University of Minnesota Dr. Richard Champlin, M.D. Anderson Cancer Center
(last updated May 13, 2004) This is an activity offered by CBBS, a CMA accredited provider. Physicians attending this course may report up to 13.25 hours of Category 1 credits toward the California Medical
Applications of comprehensive clinical genomic analysis in solid tumors: obstacles and opportunities
Applications of comprehensive clinical genomic analysis in solid tumors: obstacles and opportunities Vincent A. Miller, M.D. Foundation Medicine, Inc. AACR Annual Meeting 2012 Current Concepts session
Pharmacogenomic Approaches. Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain
Pharmacogenomic Approaches Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain Pharmacogenetics & Pharmacogenomics Medicine tailored to the individual Genetic information, including the
Worldwide Collaborations in Molecular Profiling
Worldwide Collaborations in Molecular Profiling Lillian L. Siu, MD Director, Phase I Program and Cancer Genomics Program Princess Margaret Cancer Centre Lillian Siu, MD Contracted Research: Novartis, Pfizer,
Evolving Challenges in Promoting Cardiovascular Health. November 4-5, 2011, BARCELONA. Final Agenda Feb 2011
Evolving Challenges in Promoting Cardiovascular Health November 4-5, 2011, BARCELONA Final Agenda Feb 2011 SATELLITE PUBLIC LECTURE (LAY PUBLIC): Thursday, November 3, 2011 7:00 8:30 PM Health and Life
UPDATE ON ABDOMINAL CONTRAST-ENHANCED ULTRASOUND
Under the auspices of ESFUMB ORGANIZED BY Director Concepción Bru, M.D. Hospital Clinic. Barcelona Annalisa Berzigotti, M.D. Hospital Clinic. Barcelona Rosa Gilabert, M.D. Hospital Clinic. Barcelona 2
Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions
Madrid International Bariatric Endoscopy
2 nd international course Madrid International Bariatric Endoscopy www.mibemeeting.com MIBE 2015 Madrid International Bariatric Endoscopy 24 th and 25 th 2015 September Madrid Sanchinarro University Hospital
2011 IRCC International Conference Molecular Clinical Oncology May 26th-28th, 2011, Torino Italy
Updated May 23rd, 2011 2011 IRCC International Conference Molecular Clinical Oncology May 26th-28th, 2011, Torino Italy Thursday May 26 th, 2011 (afternoon) Venue: Aula Magna Rettorato 14.00 16.00 Registration
CURRICULUM VITAE 11/10/04
CURRICULUM VITAE 11/10/04 Ariana Diana RUS MD. PRESENT POSITION 2000-present Department of Physiology Faculty of Medicine University of Valencia PhD Student Cl/ Avda. Blasco Ibanez, 15 C.P. 46010 Valencia
BNC105 PHASE II RENAL CANCER TRIAL RESULTS
ABN 53 075 582 740 ASX ANNOUNCEMENT 19 March 2014 BNC105 PHASE II RENAL CANCER TRIAL RESULTS Results show BNC105 utility in patients with advanced disease Identified biomarkers which correlate with patient
Definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents
Definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents Department Hospital Town Country Christophe Le Tourneau Medical Oncology Institut Curie Paris France
MOLOGEN AG German Equity Forum 2015
German Equity Forum 2015 Dr. Mariola Söhngen Chief Executive Officer Frankfurt am Main 24 November 2015 We are Pioneers in the Field of Immunotherapies Biotechnology company with focus on immunotherapies
Cellular, Molecular, and Biochemical Targets in Breast Cancer
Cellular, Molecular, and Biochemical Targets in Breast Cancer Kristy Kummerow Ingrid Meszoely December 12, 2012 VUMC Resident Bonus Conference One size fits all surgical treatment of breast cancer Wilhelm
AUDITORIUM ALFREDO KRAUS
AUDITORIUM ALFREDO KRAUS LAS PALMAS DE GRAN CANARIA JUNE 27-29th 2014 Organized by: Activity accredited by the Catalan Council for Continuing Medical Education 09/10879-MD 1,6 Credits groupgem.org Organizing
targeted therapy a guide for the patient
targeted therapy FOR LUNG CANCER a guide for the patient TABLE OF CONTENTS lung cancer basics... 2-3 Gene changes... 4-5 Testing... 7-8 Targeted therapy... 9-11 Drugs Targeting EGFR... 12 Drugs Targeting
9 th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPD/C) 9th International Symposium
9 th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPD/C) 9th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPD/C) Szeged,
- PRELIMINARY PROGRAM -
- PRELIMINARY PROGRAM - MADRID. SPAIN, JUNE 9 th - 10 th 2011 SALÓN DE ACTOS CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS CSIC C/ SERRANO 117, 28006 MADRID THURSDAY, 9 th June 2011 7.45 8.30 REGISTRATION
Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns
July 2013 Edition Vol. 7, Issue 7 Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns By Julie Katz, MPH, MPhil Biomarkers played a prominent role in the research presented in
British Thoracic Oncology Group (BTOG) Annual Report - April 2014 to March 2015
0116 250 2811 dawn.mckinley@uhl-tr.nhs.uk www.btog.org @BTOGORG British Thoracic Oncology Group (BTOG) Annual Report - April 2014 to March 2015 BTOG s Aim BTOG is the multi-disciplinary group for professionals
Registrations: www.doctaforum.com/gecp
Chair: Rafael Rosell Under the Auspices of: Registrations: www.doctaforum.com/gecp Thursday, 21 st of November 2013 08:00-10:00 CLINICAL SESSION Isabel lbover Fundación Hospital Son Llàtzer, Palma de Mallorca
How To Contact Cotransa
COTRANSA - Key Contact Details Physical address: MADRID (HEAD OFFICE) Avda Central, Parcela 2.5, Naves 1 y 3. 28042 Centro de carga aerea Marid-Barajas Madrid (SPAIN) Tel: +34 917 46 06 80 Fax: +34 913
Pertuzumab in Trastuzumab- Treated, Advanced HER2-Positive Breast Cancer
Pertuzumab in Trastuzumab- Treated, Advanced HER2-Positive Breast Cancer For more visit ResearchToPractice.com/5MJC CME INFORMATION OVERVIEW OF ACTIVITY Each year, thousands of clinicians and basic scientists
18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer
News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck
Corporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
Opportunities and Challenges in Translating Novel Discoveries into Useful Clinical Tests
Opportunities and Challenges in Translating Novel Discoveries into Useful Clinical Tests James H. Doroshow, M.D. NCI Deputy Director for Clinical and Translational Research NCI Workshop: Evidence Needed
Belgium Ghent University, Ghent Rigshospitalet, Copenhagen. Denmark. Germany UniversitätKlinikum, Essen Heidelberg University Hospital, Heidelberg
We are ready to actively participate in the development of innovative therapies that will improve the cure rate and quality of life of children with cancer. Created in 2003, ITCC is a consortium of 49
I N V E S T O R P R E S E N TAT I O N B I O T R I N I T Y L o n d o n A p r i l 2 0 1 6
I N V E S T O R P R E S E N TAT I O N B I O T R I N I T Y L o n d o n A p r i l 2 0 1 6 DISCLAMER This document has been prepared by Oryzon Genomics, S.A. exclusively for use during the presentation. Oryzon
Evaluation of focal adhesions as new therapeutic targets in acute myeloid leukemia
Evaluation of focal adhesions as new therapeutic targets in acute myeloid leukemia Dr Jordi Sierra Gil IRHSP Institut de Recerca Hospital de la Santa Creu i Sant Pau Dr. Miguel Ángel Sanz Alonso Fundación
Médecine de précision médecine personnalisée en Oncologie. Fabien Calvo, Directeur Recherche et Innovation, INCa, Directeur ITMO Cancer, AVIESAN
Médecine de précision médecine personnalisée en Oncologie Fabien Calvo, Directeur Recherche et Innovation, INCa, Directeur ITMO Cancer, AVIESAN Successful targeted drug development Rapid identification
New Directions in Treatment of Ovarian Cancer. Amit M. Oza Princess Margaret Hospital University of Toronto
New Directions in Treatment of Ovarian Cancer Amit M. Oza Princess Margaret Hospital University of Toronto Newly diagnosed: scenario Ist line Surgery chemotherapy Cure If can t cure can we turn into chronic
E UROPEAN PERSONAL INFORMATION
E UROPEAN CURRICULUM VITAE FORMAT PERSONAL INFORMATION Name Work Address ARTURO CHITI Humanitas University, Via A. Manzoni 113, 20089 Rozzano (MI), Italy Nuclear Medicine Department, Humanitas Research
Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference
Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Two New Clinical Programs and Significant Expansion of Cancer Pipeline Planned for 2004 SOUTH SAN FRANCISCO, Calif., Jan. 13 /PRNewswire-FirstCall/
Successes and Limitations of Targeted Therapies in Renal Cell Carcinoma
g Tumor Res. Basel, Karger, 2014, vol 41, pp 98 112 (DOI: 10.1159/000355906) Successes and Limitations of Targeted Therapies in Renal Cell Carcinoma Marc Pracht Dominik Berthold Medical Oncology Unit,
ADDARIO LUNG CANCER MEDICAL INSTITUTE
ADDARIO LUNG CANCER MEDICAL INSTITUTE Dedicated to catalyzing and accelerating the discovery, development and delivery of new and more effective treatment options for lung cancer patients. Contact: Steven
Immunotherapy Concept Turned Reality
Authored by: Jennifer Dolan Fox, PhD VirtualScopics Inc. jennifer_fox@virtualscopics.com +1 585 249 6231 Immunotherapy Concept Turned Reality Introduction While using the body s own immune system as a